GlassScriptPhysician profile
Stephen R Adams
NPI 1245363993
$636,342.13
in general payments reported to CMS, 2019-2025
35 companies · $60K in 2025
The $60K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86K · 2020: $49K · 2021: $68K · 2022: $88K · 2023: $133K · 2024: $153K · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $263K · Travel and Lodging: $58K · Food and Beverage: $17K · Consulting Fee: $8,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $262,665.00 |
| Travel and Lodging | $57,707.12 |
| Food and Beverage | $16,826.90 |
| Consulting Fee | $8,220.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $539,394.37 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $89,128.25 | 2019-2025 | Biktarvy, Sunlenca |
| Abbvie INC. | $943.55 | 2021-2025 | Vraylar |
| Merck Sharp & Dohme LLC | $939.10 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Otsuka America Pharmaceutical, INC. | $812.50 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Biotech, INC. | $663.20 | 2019-2023 | Symtuza |
| Neurocrine Biosciences, INC. | $462.80 | 2022-2025 | Ingrezza |
| Napo Pharmaceuticals INC | $442.41 | 2020-2025 | Mytesi |
| Emd Serono, INC. | $413.79 | 2019-2025 | |
| Vanda Pharmaceuticals INC. | $405.64 | 2023-2025 | Fanapt, Hetlioz |
| Janssen Products, LP | $397.94 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $262.86 | 2019-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $227.06 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $223.30 | 2020-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $212.00 | 2022-2024 | Caplyta |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $211.06 | 2019-2024 | Repatha, Otezla |
| Novo Nordisk INC | $174.14 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Antares Pharma, INC. | $156.23 | 2019-2024 | Xyosted |
| Alkermes, INC. | $151.18 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Supernus Pharmaceuticals, INC. | $112.65 | 2019-2023 | Qelbree, Tlando, Xyosted |
| Lilly USA, LLC | $92.24 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Janssen Scientific Affairs, LLC | $80.72 | 2023 | Symtuza |
| Takeda Pharmaceuticals U.S.A., INC. | $79.95 | 2020-2023 | Trintellix |
| Axsome Therapeutics, INC. | $78.54 | 2023-2024 | Auvelity |
| Glaxosmithkline, LLC. | $51.49 | 2025 | Blujepa |
| Vbi Vaccine (Delaware) INC. | $43.89 | 2022-2023 | Prehevbrio |
| Pfizer INC. | $30.93 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $26.80 | 2020-2024 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.31 | 2021 | |
| Mylan Institutional INC. | $23.08 | 2019 | |
| Hologic Sales and Service, LLC | $22.98 | 2025 | Thinprep 2000 Processor, Aptima |
| Halozyme INC | $17.04 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $13.57 | 2025 | Cobenfy |
| Allergan, INC. | $12.15 | 2020 | |
| Novartis Pharmaceuticals Corporation | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.